Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five

Zhanyu Wang1, Chengming Liu1, Sufei Zheng2

  • 1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Cancer Cell
|May 24, 2024
PubMed

Insights

Neuroendocrine carcinomas (NECs) are classified into five subtypes based on key regulators like ASCL1 and NEUROD1. This new classification reveals subtype-specific traits and therapeutic vulnerabilities in these rare cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Neuroendocrine carcinomas (NECs) are aggressive, rare malignancies with diverse origins.
  • Heterogeneity within and between NEC tissues complicates characterization and treatment.

Purpose of the Study:

  • To integrate analyses of over 1,000 NECs from 31 tissues.
  • To define intrinsic subtypes of pan-tissue NECs based on molecular drivers.
  • To characterize subtype-specific features, including transcriptional programs, genomic alterations, and therapeutic vulnerabilities.

Main Methods:

  • Integrative analysis of multi-tissue NEC genomic and transcriptomic data.
  • Identification of key transcriptional regulators defining NEC subtypes.
  • Comprehensive profiling of identified subtypes.

Main Results:

  • NECs exhibit tissue-independent convergence and molecular divergence driven by distinct transcriptional regulators.
  • Five intrinsic NEC subtypes were defined: ASCL1, NEUROD1, HNF4A, POU2F3, and YAP1.
  • A novel HNF4A-dominated subtype (H) shows gastrointestinal features, wild-type RB1, unique differentiation, poor response to chemotherapy, and large-cell morphology.

Conclusions:

  • A unified classification paradigm for NECs based on transcriptional regulators.
  • Illuminates the molecular basis of NEC heterogeneity across lineages and cytomorphologies.
  • Highlights context-dependent subtype prevalence and phenotypic disparities, guiding future research and therapeutic strategies.